Trial Profile
Single Dose Pharmacokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
- Focus Pharmacokinetics
- 16 May 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 02 Feb 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jan 2015 New trial record